The Gut Trimethylamine Cycle: Microbial Ecology, Quantitative Metabolic Flux, and Therapeutic Targeting

Abstract

Trimethylamine (TMA) and its hepatic oxidation product, trimethylamine N-oxide (TMAO), form a pivotal gut–liver metabolic axis linking the intestinal microbiota with host cardiometabolic health. Elevated plasma TMAO levels have been consistently associated with atherosclerosis, chronic kidney disease, diabetes, and other metabolic disorders. This review systematically summarizes current advances in understanding the microbial ecology and biochemical pathways underlying the gut TMA cycle. We highlight three major microbial routes for TMA generation—cutC/D-mediated choline cleavage, cntA/B-dependent carnitine oxidation, and BbuA-associated γ-butyrobetaine reduction - as well as methanogenic and acetogenic pathways responsible for TMA utilization and detoxification. Integrating multi-omics data with metabolic-flux modeling provides quantitative insight into the gut–liver TMA network, revealing key rate-limiting nodes and interindividual variability driven by diet and microbial composition. Emerging intervention strategies include chemical inhibition of cutC/D, cntA/B activity, dietary modulation, probiotic or engineered consortia enhancing TMA clearance, and bacteriophage-based precision targeting of TMA-producing taxa. Finally, we propose developing a gut TMA index and mapping producer–degrader interaction networks as frameworks for personalized risk evaluation and therapeutic design. Collectively, quantitative and translational studies of the TMA cycle are expected to establish new paradigms for microbiome-driven prevention and treatment of cardiometabolic diseases.